TIcaGrEloR and ABSORB Bioresorbable Vascular Scaffold Implantation for Recovery of Vascular Function After Successful Chronic Total Occlusion Recanalization

Inclusion Criteria: * Patients of both sexes, older than 18 years old. * Written informed consent obtained. * Patients with stable angina pectoris (Canadian Cardiovascular Society (CCS) Class 1, 2, 3 or 4) or patients with documented silent ischemia by stress test during the last year. * Patients eligible for coronary revascularization in a coronary chronic total occlusion, which was angiographically documented in a previous coronary angiography during the last year. Exclusion Criteria: * Women who are pregnant or women of childbearing potential who do not use adequate contraception. * Known allergies to aspirin, clopidogrel bisulfate (Plavix ®), ticagrelor (BriliqueTM) heparin, or a sensitivity to contrast media, which cannot be adequately pre-medicated. * Participation in other studies. * Life expectancy of less than one year or factors making clinical and/or angiographic follow-up difficult. * Planned cardiac surgery or major non-cardiac surgery. * The subject has a history of bleeding diathesis or coagulopathy. * The subject suffered disabling stroke within the past year. * Known major hematologic, neoplastic, metabolic, gastrointestinal or endocrine dysfunction, which, in the judgment of the Investigator, may affect the patient's ability to complete the study. * History of malignancy, except in patients who have been disease-free \>5 years or whose only malignancy has been basal or squamous cell skin carcinoma. * Inability to provide informed consent